Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Index investing focuses on steady, broad exposure to markets, helping you grow wealth over the long run with reduced complexity and lower costs.
27,799 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Life360 faced a tough week as investors digested a mixed earnings report. This article explains the drivers behind th...
Evaxion's Q1 2026 results shed light on how its AI-driven drug discovery model is translating into collaborations and...
A hantavirus outbreak can spark biotech chatter, but three solid realities—limited demand, tough development paths, a...
Duolingo stock crashing has sparked a flurry of headlines. This guide breaks down the causes, what it means for the b...
As COMPUTEX 2026 approaches, investors wonder if will NVIDIA stock rise. This guide breaks down the event's potential...
In March, the stock market today shows AI headlines driving trades. This article breaks down what moved markets, why ...
Nvidia has built an AI powerhouse, but its stock sits at a valuation that invites scrutiny. This guide breaks down wh...
Women are breaking into top-paying, traditionally male-dominated fields. In 2026, surgeons, airline pilots, and softw...
GLP-1 drugs like Ozempic and Wegovy are changing the cost landscape for retirees. This guide breaks down what Medicar...
If you're weighing two ad-tech stocks, this guide breaks down how to think about should zeta global stock versus AppL...
A single conference-call moment changed the mood around Eli Lilly. By unpacking eight key themes from the CEO, invest...